Enzychem Lifesciences Corporation

KOSDAQ:A183490 Stock Report

Market Cap: ₩102.8b

Enzychem Lifesciences Valuation

Is A183490 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A183490 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A183490's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A183490's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for A183490?

Key metric: As A183490 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A183490. This is calculated by dividing A183490's market cap by their current revenue.
What is A183490's PS Ratio?
PS Ratio1.2x
Sales₩82.07b
Market Cap₩102.83b

Price to Sales Ratio vs Peers

How does A183490's PS Ratio compare to its peers?

The above table shows the PS ratio for A183490 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.6x
A204840 GL Pharm Tech
2.8xn/a₩77.7b
A009300 Sam-A Pharm
1.1xn/a₩107.4b
A003120 Ilsung Is
1.5xn/a₩111.4b
A330350 WITHUS PHARMACEUTICALLTD
0.8xn/a₩89.0b
A183490 Enzychem Lifesciences
1.2xn/a₩102.8b

Price-To-Sales vs Peers: A183490 is good value based on its Price-To-Sales Ratio (1.2x) compared to the peer average (1.6x).


Price to Sales Ratio vs Industry

How does A183490's PS Ratio compare vs other companies in the KR Pharmaceuticals Industry?

3 CompaniesPrice / SalesEstimated GrowthMarket Cap
A009290 Kwang Dong Pharmaceutical
0.1xn/aUS$161.67m
A002620 Jeil Pharma Holdings
0.2xn/aUS$94.48m
A000230 Ildong Holdings
0.1xn/aUS$56.43m
No more companies available in this PS range
A183490 1.2xIndustry Avg. 0.8xNo. of Companies15PS00.81.62.43.24+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: A183490 is expensive based on its Price-To-Sales Ratio (1.2x) compared to the KR Pharmaceuticals industry average (0.8x).


Price to Sales Ratio vs Fair Ratio

What is A183490's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A183490 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.2x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A183490's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies